Key result
Perioperative hyperlactatemia is not associated with 30-day neurological disability changes after brain tumor craniotomy.
Why the study?
Hyperlactatemia is common during brain tumor craniotomy, but its pathophysiology and association with clinical outcomes are unclear.
Does perioperative hyperlactatemia affect short-term outcomes in patients undergoing elective brain tumor craniotomy?
Observational (n=450)
Does perioperative hyperlactatemia affect short-term outcomes in patients undergoing elective brain tumor craniotomy?
Perioperative hyperlactatemia is common during elective brain tumor craniotomy but is not associated with adverse short-term neurological or clinical outcomes.
Hyperlactatemia may not signal worse short-term outcomes after elective craniotomy; leaves open whether it warrants monitoring or targeted intervention in future trials.
Background: Hyperlactatemia is common during brain tumor craniotomy, although the pathophysiology and association to outcome are unclear. We prospectively investigated prevalence and risk factors for perioperative hyperlactatemia (S-lactate ≥2.2 mM) as well as its association with short-term outcomes in patients undergoing elective brain tumor craniotomy. Methods: In 450 patients, arterial lactate was measured hourly from the first surgical incision until 6 hours postoperatively. The primary outcome was a change in the level of neurological disability, measured by the modified Rankin Scale preoperatively and at 30 days after surgery. Secondary outcomes were length of hospital stay, new neurological deficits at discharge, days alive and out of hospital at 30 days, and 30-day mortality. Hyperlactatemia was analyzed both as a dichotomous (≥1 measurement of S-lactate ≥2.2 mM) and as a continuous variable (lactate load). We used both a multivariable regression and a backward stepwise regression analysis to identify risk factors for hyperlactatemia and factors associated with postoperative outcomes. Results: Hyperlactatemia was seen in 66% of the study participants. No association was found between hyperlactatemia and modified Rankin Scale change from baseline to 30 days or any other clinical outcome. Independent factors associated with hyperlactatemia were mean perioperative glucose (0.14; 95% CI: 0.09-0.18; P <0.001), preoperative glucocorticoid dose (0.09; 95% CI: 0.06-0.12, P <0.001), malignant CNS-derived tumor type (0.25; 95% CI: 0.08-0.42; P =0.004), and inverse noradrenaline dose (−0.02; 95% CI: −0.04 to −0.006, P =0.006). Conclusions: We did not find an association between perioperative hyperlactatemia and short-term outcomes in patients undergoing brain tumor craniotomy. Preoperative glucocorticoids, perioperative glucose, malignant CNS tumor, and noradrenaline dose were independently associated with hyperlactatemia.
No takes yet. Share an insight, caveat, or question.
Vassilieva et al. (2026) conducted an observational in elective brain tumor craniotomy (n=450). Perioperative hyperlactatemia was evaluated on change in the level of neurological disability, measured by the modified Rankin Scale preoperatively and at 30 days after surgery. Perioperative hyperlactatemia occurred in 66% of patients undergoing elective brain tumor craniotomy but was not associated with 30-day changes in neurological disability or other clinical outcomes.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: